Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 14/20 | 0.46 |
| ▸ | NPY1R | P25929 | 9/20 | 0.46 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.46 |
| ▸ | NPY2R | P49146 | 5/20 | 0.40 |
| ▸ | NMT2 | O60551 | 1/20 | 0.40 |
| ▸ | NMT1 | P30419 | 1/20 | 0.40 |
| ▸ | QRFPR | Q96P65 | 1/20 | 0.39 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.37 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6073057 | 1.00 | NPY4R (0.46) | NPY4RNPY1RNPY5RNPY2RNMT2 | |
| SCHEMBL29638076 | 0.94 | NPY4R (0.42) | NPY4RNPY1RNPY5RNPY2RNMT2 | |
| SCHEMBL29355526 | 0.93 | NPY4R (0.46) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL29414400 | 0.91 | NPY4R (0.43) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL29678881 | 0.91 | QRFPR (0.42) | NPY4RNPY1RNPY5RNPY2RNMT2 | |
| SCHEMBL29565556 | 0.90 | NPY4R (0.50) | NPY4RNPY1RNPY5RNPY2RNMT2 | |
| SCHEMBL29630364 | 0.90 | NMT1 (0.44) | NPY4RNPY1RNPY5RNPY2RNMT2 | |
| SCHEMBL30711719 | 0.90 | NMT1 (0.44) | NPY4RNPY1RNPY5RNPY2RNMT2 | |
| SCHEMBL29354924 | 0.89 | SLC15A2 (0.44) | NPY4RNPY1RNPY5RNPY2RNMT2 | |
| SCHEMBL29534002 | 0.89 | NPY4R (0.44) | NPY4RNPY1RNPY5RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7018633-B2 | Selective destruction of cells infected with human immunodeficiency virus | BATTELLE ENERGY ALLIANCE, LLC (US) | 2006-03-28 | — | — | US | disclosed |
| US-20040048784-A1 | Selective destruction of cells infected with human immunodeficiency virus | BATTELLE ENERGY ALLIANCE, LLC | 2004-03-11 | — | — | US | disclosed |
| US-6627197-B2 | Using variant of a protein synthesis inactivating toxin wherein a viral protease cleavage site is interposed between A and B chains; treatment of human immunodeficiency virus | BECHTEL BWXT IDAHO, LLC | 2003-09-30 | — | — | US | disclosed |
| US-20020094334-A1 | Selective destruction of cells infected with human immunodeficiency virus | BATTELLE ENERGY ALLIANCE, LLC | 2002-07-18 | — | — | US | disclosed |
| WO-2001060393-A1 | SELECTIVE DESTRUCTION OF CELLS INFECTED WITH HUMAN IMMUNODEFICIENCY VIRUS | BECHTEL BWXT IDAHO, LLC (US) | 2001-08-23 | — | — | WO | disclosed |